** German supplier of pharma and lab equipment Sartorius
SATG.DE jumps around 8% after U.S. peer Danaher's DHR.N
second-quarter profit beat estimates
** Comments on sustained positive momentum in Danaher's
bioprocessing business seem "enough to pull people back in post
the Sartorius cut on Friday," a trader says
** "Danaher, a close U.S. peer, reiterated FY24 guidance,
essentially implying lower risk for further downgrades in the
near-term," an analyst at Berenberg says
** Shares in its French subsidiary Sartorius Stedim Biotech
STDM.PA also rise around 7%
(Reporting by Isabel Demetz)
((Isabel.demetz@thomsonreuters.com))